Clinical development of voruciclib to be advanced and new formulation of ME-344 to be enabled April 16, 2024
First Patient Dosed in First-in-Human Ph 1/2 Trial of BBI-825 in Patients with Resistance Gene Amplifications April 16, 2024
REJOICE-Ovarian01 Ph 2/3 Trial of Raludotatug Deruxtecan Initiated in Platinum-Resistant Ovarian Cancer April 9, 2024
Ph 3 Trial of MK-1084 + KEYTRUDA for 1L Treatment of Certain Patients With Metastatic NSCLC initiated April 9, 2024
Alliance A032103 (MODERN) Randomized, Ph 2/3 Adjuvant Trial in Urothelial Cancer announced April 9, 2024
Enrollment in Part 2 dose expansion initiated in LOTIS-7 Trial of ZYNLONTA® + Glofitamab or Mosunetuzumab in Patients with R/R B-cell NHL April 9, 2024
Steering Committee Update Provided on Ph 3 REGAL Study with Positive Topline Data Announcement from Ph 2a Study of SLS009 in R/R AML April 2, 2024
Completion of Enrollment Announced in AUGMENT-101 Pivotal Trial Cohort of Patients with R/R mNPM1 AML April 2, 2024
First Participant dosed in Ph 3 Study (Neoshot) of IBI310 + Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy April 2, 2024
First Patient Dosed in Ph 1/2a Trial of IMM-6-415 in Advanced Solid Tumors with RAF/RAS Mutations April 2, 2024
First Patient Dosed in Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C+ve Solid Tumors April 2, 2024
Enrollment of 190 Patients to Support Primary Endpoint Analysis in SELECT-MDS-1 Ph 3 Trial completed April 2, 2024
Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy Announced April 2, 2024
Enrollment Initiated in 12-Patient Expansion Cohort of Voruciclib + Venetoclax in Ongoing Ph 1 Study April 2, 2024
Progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia reported April 2, 2024
ARYA-3 Clinical Trial Advances to Ph 2 for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS T-cell Therapy March 26, 2024
First patient dosed in Ph 1b/2 trial of LB-100 + dostarlimab-gxly in ovarian clear cell carcinoma March 26, 2024
Enrollment Completed for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with R/R PCNSL March 26, 2024
Lacutamab monotherapy development in PTCL to be discontinued after the anti-KIR3DL2 antibody fell short in Ph Ib trial March 26, 2024
